摘要
目的:探究雷珠单抗在新生血管性青光眼治疗中的有效性与安全性。方法:选取2017年1月—2018年5月我院收治的60例新生血管性青光眼患者,根据治疗方法的不同分为实验组对照组,每组例数为30例。实验组给予雷珠单抗联合常规治疗,对照组仅给予常规治疗,观察两组患者眼压、术后并发症出现率、术后视力恢复情况。结果:实验组治疗后1周、1个月、3个月眼压低于对照组(28.25±1.25<40.69±1.87;21.97±1.58<30.36±1.88;16.97±1.27<25.41±1.39)mmHg;实验组治疗后视力小于0.1、0.1～0.2均小于对照组(6.67%<36.67%;13.33%<43.33%);视力大于0.2～0.6、大于0.6高于对照组(43.33%>16.67%;36.67%>33.33%);术后并发症总出现率小于对照组(10.00%<36.67%),组间差异值为P均<0.05。结论:在新生血管性青光眼治疗中加用雷珠单抗不仅有利于改善眼压,更利于改善视力,降低术后并发症出现率,具有独特的优势。
Objective: To investigate the efficacy and safety of Lei Zhu McAb in the treatment of neovascular glaucoma. Methods: From January 2017 to May 2018, 60 patients with neovascular glaucoma were divided into experimental group (n=30) and control group (n=30). The experimental group was given the combined routine therapy of Lei Zhu McAb and the control group was given the routine treatment. The IOP, the incidence of postoperative complications and the recovery of visual acuity were observed in the two groups. Results: The IOP in the experimental group was lower than that in the control group 1 week, 1 month and 3 months after treatment(28.25±1.25<40.69±1.87;21.97±1.58<30.36±1.88;16.97±1.27<25.41±1.39)mmHg;treatment, the visual acuity less than 0.1% was less than that in the control group (6.67%<36.67%<13.33%<43.33%). The visual acuity between 0.2~0.6,and above 0.6 was higher than that of the control group (43.33%>16.67%>36.67%>33.33%). The total incidence rate of postoperative complications was lower than that of control group (10.00%<36.67%), and the difference between groups was P<0.05. Conclusion: The application of Leizhu McAb in neovascular glaucoma treatment is not only beneficial to improve intraocular pressure, but also to improve visual acuity and reduce the occurrence rate of postoperative complications. It has unique advantages and is worthy of further popularizing and applying in clinic.
作者
陈瑞强
郭玉强
CHEN Rui-qiang;GUO Yu-qiang(Puyang ophthalmology hospital ophthalmology zip code, Puyang Henan 457000,China)
出处
《药品评价》
CAS
2019年第6期36-38,51,共4页
Drug Evaluation
